news
FDA's TEMPO pilot lets AI medical devices launch pre-authorization
The FDA's new TEMPO pilot program is letting companies like Cadence and Limbic release generative AI medical devices to patients without full marketing authorization first. This means certain digital health products for mental health support could reach users faster, shifting how we think about regulation for AI tools.
The FDA's new TEMPO pilot program is letting companies like Cadence and Limbic release generative AI medical devices to patients without full marketing authorization first. This means certain digital health products for mental health support could reach users faster, shifting how we think about regulation for AI tools.
The architecture take
The FDA's new fast-track for AI medical devices is less about accelerating innovation and more about figuring out how to regulate software that learns on the fly. Cadence's diabetes management and Limbic's mental health chatbot are in the first cohort, which makes sense. An AI for blood sugar control or anxiety support changes as it collects more data, and a static authorization doesn't account for that evolution. This pilot lets the FDA learn how to manage 'living' software that changes, potentially making sure these devices are safer over time. But it also means early users are getting devices that haven't cleared the usual bar. My take? It's a gamble, but one the FDA probably has to make, given how fast AI moves. Watch for how they define 'acceptable risk' when the software is still writing its own rules. It's less about the devices, more about the new regulatory muscle the FDA needs to build.